Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $33.33 Average Price Target from Analysts

Posted by George Bondi on Jun 27th, 2026

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) has received an average rating of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $33.3333.

A number of analysts recently issued reports on CRVS shares. Wall Street Zen downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings raised Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 29th. Oppenheimer reissued an “outperform” rating and set a $33.00 price objective (up from $32.00) on shares of Corvus Pharmaceuticals in a research report on Friday, March 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Friday, March 13th. Finally, The Goldman Sachs Group started coverage on Corvus Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $40.00 price objective for the company.

Read Our Latest Research Report on CRVS

Corvus Pharmaceuticals Stock Up 3.1%

Shares of CRVS opened at $13.46 on Friday. Corvus Pharmaceuticals has a 52-week low of $3.71 and a 52-week high of $26.95. The company has a market capitalization of $1.13 billion, a PE ratio of -25.88 and a beta of 0.84. The stock has a fifty day simple moving average of $13.49 and a two-hundred day simple moving average of $13.91.

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, equities analysts anticipate that Corvus Pharmaceuticals will post -0.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director David Scott Moore bought 21,700 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the acquisition, the director directly owned 21,700 shares of the company’s stock, valued at $250,201. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 19.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP purchased a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $27,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Corvus Pharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock valued at $28,000 after acquiring an additional 748 shares during the period. Russell Investments Group Ltd. purchased a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $49,000. Sender Co & Partners Inc. purchased a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $52,000. Finally, Bayesian Capital Management LP purchased a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $70,000. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

About Corvus Pharmaceuticals

(Get Free Report)

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.